Bio-Path Holdings, Inc. (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year 2012.
2012 OPERATIONAL AND FINANCIAL HIGHLIGHTS
Enrollment continues in the Phase I clinical trial of Bio-Path’s lead antisense cancer drug product Liposomal Grb-2 (BP-100-1.01).
